Uponor Corporation
Uponor Corporation Managers’ Transactions 16 February 2021 09:15 EET
Notification of transactions by managers and their closely associated persons: Minna Yrjönmäki
Notification under the EU Market Abuse Regulation, article 19
Person subject to the notification requirement
Name: Yrjönmäki, Minna
Position: Chief Financial Officer
Issuer: Uponor Corporation
LEI: 743700KA2GMSYJM3CM12
Notification type: INITIAL NOTIFICATION
Reference number: 743700KA2GMSYJM3CM12_20210215134801_49
____________________________________________
Transaction date: 2021-02-15
Venue not applicable
Instrument type: SHARE
ISIN: FI0009002158
Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE
Transaction details
(1): Volume: 1469 Unit price: 0.00 EUR
Aggregated transactions
(1): Volume: 1469 Volume weighted average price: 0.00 EUR
Uponor Corporation
Susanna Inkinen
Vice President, Communications and Corporate Responsibility
Tel. +358 20 129 2081
DISTRIBUTION:
Nasdaq Helsinki
Media
www.investors.uponor.com
Uponor in brief
Uponor is rethinking water for future generations. Our offering, including safe drinking water delivery, energy-efficient radiant heating and cooling and reliable infrastructure, enables a more sustainable living environment. We help our customers in residential and commercial construction, municipalities and utilities, as well as different industries to work faster and smarter. Uponor employs about 3,700 professionals in 26 countries in Europe and North America. In 2020, Uponor's net sales totalled approximately €1.1 billion. Uponor Corporation is based in Finland and listed on Nasdaq Helsinki. www.uponor.com
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Biotalys NV18.9.2025 07:00:00 CEST | Press release
Biotalys Reports Half-Year 2025 Financial Results and Business Highlights
F. Hoffmann-La Roche Ltd18.9.2025 07:00:00 CEST | Press release
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
Ascom Holding AG18.9.2025 06:30:00 CEST | Press release
Michael Reitermann takes over the operational leadership of the Ascom Group as Delegate of the Board of Directors and interim CEO
Novo Nordisk A/S17.9.2025 23:05:02 CEST | Press release
Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Biogen Inc.17.9.2025 22:30:05 CEST | Press release
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom